We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
KT-HEALTHC RMF NAV, returns and fees — KTAM World Healthcare RMF | Robowealth
KT-HEALTHC RMF invests through the master fund Janus Henderson Global Life Sciences Fund 98.97%
Master fund data as of 30 Sep 2026
This fund
KT-HEALTHC RMF
Invests in units of another fund
→
The fund that actually invests
Janus Henderson Global Life Sciences Fund
H2 · Ireland
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
The fund spreads its money across many companies
Top 10 companies combined 43.41% of fund value
Other stocks and cash
The fund's allocation: Eli Lilly and Co 9.51%, Johnson & Johnson 7.70%, ABBVIE 4.88%, Unitedhealth Group 4.23%, AstraZeneca 3.67%, Thermo Fisher 3.32%, Novartis 2.70%, Roche 2.65%, argenx 2.42%, Merck & 2.33%, and other stocks and cash 56.59%
Past performance is not a guarantee of future results
Go deeper
Yearly returns
Up in 6 of 10 years · best 2019 +24.33% · worst 2016 −15.54%
Monthly returns
Positive months: 77 of 132 (58%) · Best Apr 2020 +12.33% · Worst Jan 2016 −14.09%
Tap a year to see its months · * part year
Year
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
+0.1
+1.5
−5.5
+1.2
+1.8
+8.4
−0.7
+3.2
−4.1
+6.6
+2.6
·
2025
+5.4
−0.0
−4.1
−2.5
−6.8
+1.5
−0.9
+5.4
+2.2
+8.3
+8.7
−1.4
2024
+2.6
+3.8
+1.5
−4.8
+2.9
+2.7
+1.7
+3.4
−3.4
−2.6
−1.1
−8.1
2023
−0.6
−4.1
+1.6
+3.6
−2.7
+2.7
−0.1
−1.6
−3.5
−7.1
+6.4
+6.6
2022
−12.7
+4.1
+3.5
−6.4
−1.2
−0.3
+4.9
−3.8
−2.8
+8.1
+3.7
−1.7
2021
−0.9
+0.2
−2.8
+3.8
+0.1
+4.5
−0.1
+2.2
−3.2
+3.9
−7.5
+6.5
Average
−0.4
+0.1
−0.9
+0.9
+0.2
+3.0
+1.6
+0.9
−1.5
−0.1
+3.3
−0.1
Holding returns: worst · median · best
Every start date since 30 Nov 2015 · 3 and 6 months are total % · 1 year and over is % per year
Worst to best (green = gain, red = loss)Half of all outcomes fall in this rangeMedian
Risk
Drawdown from peak
Largest drawdown in the selected period −26.77%Previous peak 21 Feb 2020 (NAV 12.3703) → Trough 23 Mar 2020 (NAV 9.0588) · Back to the previous peak on 19 Jun 2020, after 2 months
Currently −0.29% from the peak NAV of 18.5052 (9 Nov 2026)
Change between the 2 points
Below the previous peakLargest drawdown period (previous peak → recovery)Drawdown = NAV ÷ highest prior NAV in the selected period − 1Drag across the chart to pick 2 points (on a phone, hold with 2 fingers)
กองทุนเน้นลงทุนในหน่วยลงทุนของกองทุน Janus Henderson Global Life Sciences Fund (Master Fund) เพียงกองเดียว โดยเฉลี่ยในรอบปีบัญชี ไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุนรวม หรือตามอัตราส่วนที่สำนักงานคณะกรรมการ ก.ล.ต. จะประกาศกำหนด Its largest holdings are หน่วยลงทุน Janus Global Life Sciences Fund 99.59% (fact sheet 30 Sep 2026)
How risky is it?+−
Risk level 7 of 8 (High risk). Since 30 Nov 2015, its NAV has fallen as much as −26.77% from its peak.
What are the fees?+−
Actual total expense ratio (TER) 1.97% a year, against a ceiling of 5.35%. Management fee 1.34%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
Does it pay dividends?+−
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Next in lineThermo Fisher Laboratory instruments 3.32%Novartis Hospitals and medical services 2.70%Roche Hospitals and medical services 2.65%argenx Vyvgart 2.42%Merck & Hospitals and medical services 2.33%
Based on the master fund's share of this fund's value (98.97% as of 31 Aug 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
+3.94%/yr
17.80%
−23.26%
+0.22
7Y
+66.59%+7.56%/yr
19.71%
−26.77%
+0.38
10Y
+108.71%+7.63%/yr
18.29%
−26.77%
+0.42
MAX
+84.55%+5.75%/yr
18.50%
−26.77%
+0.31
Return
MDD
SD
Return/SD
1Y
+18.61%
−9.37%
17.89%
+1.04
3Y
+46.06%+13.46%/yr
−23.26%
17.23%
+0.78
5Y
+21.33%+3.94%/yr
−23.26%
17.80%
+0.22
7Y
+66.59%+7.56%/yr
−26.77%
19.71%
+0.38
10Y
+108.71%+7.63%/yr
−26.77%
18.29%
+0.42
MAX
+84.55%+5.75%/yr
−26.77%
18.50%
+0.31
3Y
Top 25% of the group
Rank 2 of 9 funds
Return +13.46% per year
3Y returns of 9 funds in the Health Care group, sorted from highest to lowest. This fund ranks 2
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Only RMF share classes are counted, and only funds with a full track record for the period are included · Calculated from NAV as of 13 Nov 2026
What is the minimum purchase, and when do I get my money after selling?+−
Minimum first purchase 500 THB, subsequent purchases 500 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
How does the tax deduction work?+−
KT-HEALTHC RMF is a retirement mutual fund (RMF). You can buy up to 30% of your assessable income, capped at 500,000 THB a year together with other retirement funds. You must hold it for at least 5 years and can sell only once you turn 55. Check the latest conditions with the Revenue Department before investing
Does it hedge currency risk?+−
Hedged at the manager's discretion. As of 30 Sep 2026, 70.83% of the value of its foreign investments was hedged